Creative Medical Technology Holdings, Inc. reported its financial results for the second quarter and six months ended June 30, 2025. For the three months ended June 30, 2025, the company reported no revenue, a decrease from $8,000 in the comparable prior-year period. For the six months ended June 30, 2025, revenue was $3,000, down from $8,000 in the prior year.
The net loss for the six months ended June 30, 2025, was $2.87 million, compared to a net loss of $2.60 million in the prior-year period. Selling, general and administrative (SG&A) expenses for the six months increased by 20% to $1.62 million, primarily due to a $169,213 increase in marketing expenses and higher legal and public company costs. Research and development (R&D) expenses for the six months totaled $1.24 million, an 8% decrease year-over-year, driven by reallocations within clinical trials.
From a liquidity standpoint, CELZ reported $6.54 million in available cash and US Treasuries as of June 30, 2025, with positive working capital of approximately $6.36 million. This represents an increase from $5.94 million in cash and $5.81 million in working capital at December 31, 2024. The improvement in liquidity was significantly aided by $3.35 million in net cash received from the exercise of warrants during the six months ended June 30, 2025. Net cash used in operating activities increased by 16% to $2.75 million for the six months ended June 30, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.